Dr Iain McWilliam Arrayjet's CEO commented, ''We understand that our customers are interested in performing high quality, fast paced research and that microarrays are one of the tools used to get there. We believe by developing our strategy to become a complete solutions provider we are better placed to help our customers achieve good quality data on which to make decisions, by either providing an instrument, printed slides, or a full microarray services with data analysis.''
Arrayjet's Commercial Director, Claire Jenkins said, ''I'm delighted Arrayjet and Fios Genomic are working together. It's a natural fit for the two companies and maximises the skills of both companies to provide a complete solution for customers working in areas such as proteomics and biomarker discovery and validation''.
Dr Bill Buckie, Fios Genomics’ CEO commented, ''The strategic alliance makes good commercial sense and will allow both companies’ customers to benefit from our complementary services. In particular, customers who are interested in profiling protein & peptide expression changes, such as in a clinical environment and for biomarker classification, can come to either Fios Genomics or Arrayjet for a joined up service offering including the supply of custom microarrays, sample preparation, proteomic data generation and analysis of the data”.
